KMDA

KMDA

USD

Kamada Ltd. Ordinary Shares

$6.670-0.220 (-3.193%)

实时价格

Healthcare
Drug Manufacturers - Specialty & Generic
以色列

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$6.890

最高价

$6.890

最低价

$6.660

成交量

0.03M

公司基本面

市值

386.0M

所属行业

Drug Manufacturers - Specialty & Generic

国家/地区

Israel

交易统计

平均成交量

0.06M

交易所

NMS

货币

USD

52周价格范围

最低价 $5.54当前价 $6.670最高价 $9.15

AI分析报告

最后更新: 2025年10月13日
由AI生成数据来源: Yahoo Finance, Bloomberg, SEC

KMDA's Pulse Quickens: Data Points to a Short-Term Surge for Kamada

October 13, 2025, 08:31 AM EDT

Whispers in the Headlines

The news stream around Kamada has been quiet lately, but the key events from late summer tell an important story. Back on August 11th, the company announced a solid operational win: FDA approval for its new plasma collection center in Houston. This is a tangible piece of good news that expands the company's capacity. Just two days later, the company held its Q2 earnings call. While the transcript itself is just a record, the timing is interesting. That day, August 13th, saw a huge spike in trading volume and a wide price swing, suggesting the market was reacting strongly to the financial results and commentary. These past events seem to be setting the stage for the current market mood.

The Anatomy of a Downturn

Looking at Kamada's stock chart over the last three months is like watching a slow, grinding descent. The shares tumbled from a peak above $8.00 in mid-July, falling steadily through August and September. The price eventually found a floor, bouncing multiple times in the $6.50 to $6.70 range. This area appears to be a new level of support where buyers have consistently stepped in.

The most recent price action shows a potential change in character. After hitting a low of $6.50 on October 7th, the stock has started to claw its way back up, closing the latest session at $6.80. This stabilization, after a long period of selling, is often the first sign that the balance of power might be shifting from sellers back to buyers.

The Digital Crystal Ball

The current technical picture is where things get compelling. Several indicators are flashing green, suggesting a bullish turn. We're seeing a "golden cross" in the MACD indicator, a classic signal that momentum is shifting upward. Trading volume has also surged, which confirms there's real conviction behind the recent price moves. On top of that, our AI model is forecasting a price jump of nearly 4% over the next three days with a high degree of confidence.

However, it's important to weigh this against the company's financial health. The fundamental data points to some real challenges, including very high debt and low revenue growth. This creates a clear conflict: the short-term technicals and AI predictions look strong, but the long-term business fundamentals appear weak. This suggests any current opportunity is likely a short-term trade, not a long-term investment.

The Bottom Line

For traders with a moderate appetite for risk, the data suggests a short-term opportunity in Kamada (KMDA) may be forming. The combination of a potential bottom in the stock price, strong technical buy signals, and a bullish AI forecast creates a compelling case for a quick trade over the next one to two weeks. The weak fundamentals, however, mean this is not a "buy and hold" situation.

A strategic approach could involve entering a position around the $6.77 - $6.83 levels. Given the stock's recent volatility and underlying risks, setting a firm stop-loss at $6.12 is critical to protect against a reversal. If the bullish momentum continues as the data suggests, a reasonable target to take profits would be near $7.29.


Disclaimer: This report is for informational purposes only and does not constitute financial advice, an offer to sell, or a solicitation of an offer to buy any security. The analysis is based solely on the structured data provided and may not be comprehensive. Investing in stocks involves risks, including the possible loss of principal. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

相关新闻

GlobeNewswire

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up

查看更多
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
GlobeNewswire

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025

REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for

查看更多
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025
GlobeNewswire

Kamada to Present at the Stifel 2025 Healthcare Conference

REHOVOT, Israel and Hoboken, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious

查看更多
Kamada to Present at the Stifel 2025 Healthcare Conference

AI预测Beta

AI建议

看涨

更新于: 2025年11月10日 12:05

看跌中性看涨

65.5% 置信度

风险与交易

风险等级3/5
中风险
适合于
适中
交易指南

入场点

$6.61

止盈点

$7.17

止损点

$6.02

关键因素

RSI 71.4表明超买条件
PDI 13.8高于MDI 5.4,且ADX 11.8,表明看涨趋势
当前价格非常接近支撑水平$6.61,表明有强烈的买入机会
交易量是平均值的2.6倍(1,593),表明有显著的买入兴趣
MACD 0.0059高于信号线-0.0033,表明看涨交叉

保持更新

设置价格提醒,获取AI分析更新和实时市场新闻。